2024-515504-39-00
Recruiting
Phase 1/2
A phase I dose-escalation study testing the feasibility and the tolerance of infusion of a third party suicide gene-transduced anti-HLA-DPB1*0401 cytotoxic T cell clone in patients with HLA-DPB1*0401 positive hematologic malignancies and receiving an allotransplant from HLA-DPB1*0401 negative donors
Centre Hospitalier Universitaire De Nantes1 site in 1 country6 target enrollmentSeptember 5, 2024
Overview
- Phase
- Phase 1/2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Centre Hospitalier Universitaire De Nantes
- Enrollment
- 6
- Locations
- 1
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Dr Thierry GUILLAUME
Scientific
Centre Hospitalier Universitaire De Nantes
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A First-in-Human Dose Escalation Study of JNJ-79635322, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis2023-503679-12-00Janssen - Cilag International75
Recruiting
Not Applicable
TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant TumorsNCT07266298Neowise Biotechnology24
Active, not recruiting
Phase 1
A Phase I/II study of WX-554 in solid tumoursPatients with advanced, metastatic and/or progressive solid tumours for whom there is no effective standard therapy available.MedDRA version: 14.1 Level: LLT Classification code 10049280 Term: Solid tumour System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-003408-19-GBWILEX AG50
Completed
Phase 1
Clinical trial to evaluate safety, tolerability and pharmacokinetic of herbal (ICB-014-A002) capsule in healthy adult volunteers.CTRI/2018/01/011259Indian Institute of Integrative Medicine Council of Scientific Industrial Research38
Active, not recruiting
Phase 1
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a malignant neoplasm of the central nervous systemEUCTR2018-001404-11-ITGENENTA SCIENCE SR21